MAPK3 and familial pancreatic carcinoma: However, gemcitabine in combination with OGX-011 significantly inhibited pERK1/2 activation.We therefore think that sCLU sliencing sensitizes pancreatic cancer cells to gemcitabine chemotherapy by inhibiton of ERK1/2 activation.